Revenue ₹353 Cr (+17.3% YoY)
0 met · 0 close · 3 missed across 4 tracked promises
View all executive profiles for Corona Remedies LtdCorona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exce...
0% promises delivered
Based on 4 tracked promises across 3 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
30 Apr 2026
Revenue ₹353 Cr (+17.3% YoY)
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges.
bullish
high
2 missed, 1 delayed
Read full analysis →
Q2 FY26
26 Jan 2026
Revenue ₹361 Cr (+15% YoY)
Corona Remedies delivered a solid Q2 FY26 with revenue of ₹361 crore (+15% YoY), EBITDA of ₹78.5 crore (+17.4% YoY), and PAT of ₹52 crore (+22% YoY).
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
15 Jan 2026
Revenue ₹342 Cr (+15% YoY)
Corona Remedies delivered a strong Q3 FY26 with revenue of ₹342 crore (+15% YoY), EBITDA of ₹83 crore (+20% YoY), and adjusted PAT of ₹56 crore (+24% YoY).
bullish
high
1 missed
Read full analysis →